Determining the nanoBRET AL2K IC50 values of 24 new ACVR1/ALK2 inhibitors

In an effort to develop clinical compounds for Diffused Intrinsic Pontine Glioma (DIPG) treatment, new analogues of ACVR1/ALK2 inhibitors are continuously synthesised by Ontario Institute for Cancer Research (OICR) and Charles River Laboratories (CRL). I will provide prompt feedback of the cellular assay results to guide their design of new compounds.

The blog post for this page can be found on the SGC opennotebook site:

https://openlabnotebooks.org/determining-the-nanobret-al2k-ic50-values-of-24-new-acvr1-alk2-inhibitors/